Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Online Only
FDA Oncology Update
Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer
Read More
FDA Oncology Update
Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer
Read More
FDA Oncology Update
Brukinsa Now FDA Approved for Patients with CLL or SLL
Read More
FDA Oncology Update
Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma
Read More
ASCO Highlights
PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
Read More
ASCO Highlights
Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions
Read More
ASCO Highlights
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Read More
ASCO Highlights
Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation
Read More
ASCO Highlights
ASCO Highlights Innovation as Key to Equitable Cancer Care
Read More
FDA Oncology Update
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality
Read More
1
2
3
4
Page 1 of 4
Results 1 - 10 of 36